|
|
|
||
(State or other jurisdiction
of incorporation)
|
(Commission
File Number) |
(IRS Employer
Identification No.)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading
symbol
|
Name of each exchange
on which registered
|
||
|
|
The
(Nasdaq Global Select Market)
|
(a)
|
Puma Biotechnology, Inc., a Delaware corporation (the “Company”), held the 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”) of the Company on June 13, 2023 at the Company’s principal executive offices, 10880 Wilshire Blvd., Suite 2150, Los Angeles, California.
|
(b)
|
The following proposals were voted upon at the 2023 Annual Meeting, and the final voting results with respect to each such proposal are set forth below:
|
Proposal 1:
|
The Company’s stockholders elected the eight nominated directors identified below, each to serve and to hold office for a one-year term until the close of the Company’s next annual meeting of stockholders in 2024 and until their successors have been duly elected and qualified or until their earlier resignation or removal.
|
Nominee
|
For
|
Withheld
|
Broker
Non-Votes |
Alan H. Auerbach
|
30,178,897
|
631,556
|
8,447,026
|
Alessandra Cesano
|
30,203,447
|
607,006
|
8,447,026
|
Allison Dorval
|
30,159,595
|
650,858
|
8,447,026
|
Michael P. Miller
|
30,024,166
|
786,287
|
8,447,026
|
Jay M. Moyes
|
30,138,689
|
671,764
|
8,447,026
|
Adrian M. Senderowicz
|
30,024,571
|
785,882
|
8,447,026
|
Brian Stuglik
|
27,223,850
|
3,586,603
|
8,447,026
|
Troy E. Wilson
|
26,825,653
|
3,984,800
|
8,447,026
|
Proposal 2:
|
The Company’s stockholders ratified the selection of KPMG LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2023.
|
For
|
Against
|
Abstain
|
Broker
Non-Votes |
39,051,453
|
113,960
|
92,066
|
0
|
Proposal 3:
|
The Company’s stockholders voted to approve, on an advisory basis, the compensation of the Company’s named executive officers.
|
For
|
Against
|
Abstain
|
Broker
Non-Votes |
28,584,098
|
2,112,789
|
113,566
|
8,447,026
|
PUMA BIOTECHNOLOGY, INC.
|
|||
Date: June 15, 2023
|
By:
|
/s/ Alan H. Auerbach
|
|
Alan H. Auerbach
|
|||
Chief Executive Officer and President
|